---
run_id: halo-evidence-vs-diagnosis-validation-v9-vanilla-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: vanilla
run_number: 1
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 101
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
condition_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
output_file: model-outputs/vanilla.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `vanilla`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 101, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### The Recommendation
The executive team is currently operating on "noisy" signals. Your expansion bookings are inflated by temporary pricing (financial noise), your usage spikes are driven by managers simulating scenarios rather than adjusters executing work (behavioral noise), and your support tickets have simply migrated channels (operational noise).

The **Claim File Review** is the only option that penetrates this noise to find the "ground truth": whether DraftPath actually solves a problem in the claim file. By auditing accepted vs. overridden suggestions, you move from measuring *activity* (which can be coerced by managers) to measuring *utility* (which is required for long-term retention). This provides the necessary evidence to decide if you should scale, pivot toward health-liability, or rebuild the logic entirely before the budget is spent on a product that users are currently "performing" for their bosses.

### The Strongest Reason Against It
The Claim File Review is a slow, manual qualitative process that provides a small sample size. Unlike the Usage Quality Sprint or Commercial Cleanroom, it does not produce "hard" financial or behavioral metrics that a Board typically prefers. By choosing this, you sacrifice the ability to immediately quantify the revenue impact of the bundle pricing or the precise drop-off rate of adjusters, potentially leaving the CEO feeling they lack a "statistically significant" number to present to the board.

### The Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "regional carrier" churn (the two accounts planning to remove DraftPath) was not based on product utility, but specifically on a pricing misalignment. If the primary risk is that you have accidentally trained the market to only value DraftPath at a discounted bundle price, then the problem is a commercial positioning failure rather than a product-market fit failure. In that specific case, validating the price elasticity via the Cleanroom becomes more urgent than validating the workflow utility.
